Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40B0L | ISIN: FR001400PFU4 | Ticker-Symbol: Z421
Tradegate
14.01.25
10:51 Uhr
25,600 Euro
+0,200
+0,79 %
Branche
Software
Aktienmarkt
CAC Mid 60
1-Jahres-Chart
PLANISWARE Chart 1 Jahr
5-Tage-Chart
PLANISWARE 5-Tage-Chart
RealtimeGeldBriefZeit
25,80026,00017:00
25,80026,00016:56
GlobeNewswire (Europe)
241 Leser
Artikel bewerten:
(1)

Planisware - Strong success of employee shareholding offer

Finanznachrichten News

Strong success of employee shareholding offer

  • Completion of employee share offering
  • Strong demand from employees in all regions concerned
  • Capital increase involving 370,000 newly-issued shares (0.53% of capital)

Paris, France, May 29, 2024 - Planisware, a leading B2B provider of SaaS in the rapidly growing Project Economy market, announces today the success of its offer reserved for employees, conducted concurrently with the IPO process. This offering was for a maximum of 370,000 shares to be issued, representing around 0.53% of the share capital, offered at a 30% discount to the price offered in the global Initial Public Offering to institutional investors.

369 employees (i.e. 73% of the eligible employees worldwide) participated in the offering, with the total subscription exceeding the maximum amount set for the capital increase. Following this operation, employees (current and former employees and managers of the Group) hold 7.0% of the share capital of Planisware SA.

Pierre Demonsant, Co-founder and Chairman of Planisware, commented: "I am proud of the success of this capital increase reserved for the Group's employees. Following the success of the global offering to institutional investors, this excellent level of participation is a strong signal of employee shareholder support for the Group's model and strategy. This operation will also enable us to propose a better sharing of the Group's value creation and to align everyone's interests in the Group's development."

Pursuant to the authorization granted by the Combined General Meeting of April 15, 2024, and concurrently with the Company's IPO, Planisware proposed an offer reserved for Company employees.

The offer was made to employees in France, Germany, the United States, and Canada, within the framework of company savings plans and the international group savings plan. Eligible employees were required to have at least three months' employment history and to be effectively employed on the last day of the subscription period.

As the total amount of subscriptions received exceeded the maximum nominal amount of the capital increase set as part of the offer, the company issued 370,000 new shares at a price of 11.20 euros per new share, i.e. a nominal value of 0.10 euros and a premium of 11.10 euros per share.

The newly-created shares are ordinary shares, assimilable to existing shares from the date of issue. The listing of these shares on Euronext Paris (ISIN code: FR FR001400PFU4) has been applied for as soon as they are issued.

The newly-created shares carry dividend rights, entitling their holders to dividends that may be paid in respect of the 2024 financial period.

In accordance with the French Labor Code and the provisions of employee savings plans, shares subscribed under the employee share offering will be unavailable for a period of five years, except in the event of one of the early unlocking provisions of the French Labor Code.

This increase brings the Company's share capital to € 6,976,100.00, divided into 69,761,000, each with a nominal value of € 0.10, fully subscribed and paid-up.

Upcoming events

  • July 30, 2024: H1 results publication
  • October 23, 2024: Q3 revenue publication

Contact

Investor RelationsMedia
Benoit d'AmécourtBrunswick Group
Hugues Boëton / Tristan Roquet Montégon
benoit.damecourt@planisware.complanisware@brunswickgroup.com
+33 6 75 51 41 47+33 6 79 99 27 15 / +33 6 37 00 52 57

About Planisware

Planisware is a leading business-to-business ("B2B") provider of Software-as-a-Service ("SaaS") in the rapidly growing Project Economy. Planisware's mission is to provide solutions that help organizations transform how they strategize, plan, and deliver their projects, project portfolios, programs, and products.

With close to 700 employees across 14 offices, Planisware operates at a significant scale, serving around 545 organizational clients in a wide range of verticals and functions in more than 30 countries worldwide. Planisware's clients include large international companies, medium-sized businesses, and public-sector entities.

Planisware is listed on the regulated market of Euronext Paris (Compartment A, ISIN code FR001400PFU4, ticker symbol "PLNW"). For more information, visit: https://planisware.com/

Connect with Planisware on: LinkedIn and X (formerly Twitter).


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.